Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Nexzol Pharma Inc. is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This active matter involves 1 distinct examiner and is situated within 1 distinct art unit. Such a structure shows that the company's patent office interactions are currently limited to a specific technical field. The use of a single art unit implies that the subject matter of the application is categorized under a particular regulatory framework at the patent office.
The busiest examiner for the company is SCHLIENTZ, NATHAN W, who is currently processing 1 pending office action. Because this examiner is the only one assigned to the company's pending workload, they serve as the primary point of contact for all current prosecution efforts. For a practitioner, the success of the application relies on addressing the specific concerns raised by this examiner. The absence of other pending matters means there are no conflicting examiner requirements to balance. This streamlined prosecution environment allows for a highly targeted approach to resolving the pending office action.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHLIENTZ, NATHAN W | 1 | 41.3% | -18.9% |
| Art Unit | Apps |
|---|---|
| 1616 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17560152 | TRANSDERMAL FORMULATIONS | SCHLIENTZ, NATHAN W | 1616 | §103 | Non-Final OA | 81d overdue | Pending | Dec 22, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial